Inhibitors of tyrosine kinase

A compound according to Formula (IV)

• or an optically pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein
• B is —NR6—;
• D is N;
• E is N;
• L is —O(CH2)1-5O—, —O(CH2)1-5NR6—, —NR6(CH2)1-5NR6—, —CONR6(CH2)1-5NR6—, —NR6CO(CH2)1-5NR6—, (CH2)1-5NR6—, —(CH2)1-5O—, —(CH2)1-5OCO—, —(CH2)1-5CONR6—,
• each of which is optionally substituted by one, two, three, or four R7;
• Ar is selected from the group consisting of
• R1 is H, F, Cl, Br, OH, N3, NO2, CF3, CN, methyl, ethyl, propyl, isopropyl, or -G-Ar1, wherein G is —CO—, —COO—, —CONR6—, —NR6—, —(CH2)1-5—, —O—, —OPO—, —OPO2—, —S—, —SO—, or —SO2—, Ar1 is phenyl,
• each of which is optionally substituted by F, Br, Cl, CF3, CN, N3, NH2, NO2, OH, OCH3, methyl, CH2CN, ethyl, propyl, isopropyl, or cyclopropyl;
• R2 is selected from the group consisting of H, F, Br, Cl, CF3, CN, N3, NH2, NO2, OH, OCH3, methyl, ethyl, propyl, isopropyl,
• each of which is optionally substituted by one, two, three, or four R7;
• R3 is H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, or tert-butyl, each of which can be substituted by one, two, three, or four R7;
• R4 is selected from the group consisting of H, methyl, ethyl, propyl, and isopropyl;
• or R3 and R4 together form
• R5 is selected from the group consisting of CO(CH2)0-5CH3, CONR6 (CH2)0-5CH3, COO (CH2)0-5CH3, SO2 (CH2)0-5CH3, CO(CH2)0-5CH═CH2, CONR6 (CH2)0-5CH═CH2, COO (CH2)0-5CH═CH2, SO2 (CH2)0-5CH═CH2, CO(CH2)0-5CH═CHCH3, COO (CH2)0-5CH═CHCH3, CONR6 (CH2)0-5CH═CHCH3, SO2 (CH2)0-5CH═CHCH3, CO(CH2)0-5C≡CH, COO (CH2)0-5C≡CH, CONR6(CH2)0-5C≡CH, SO2 (CH2)0-5C≡CH, CO(CH2)0-5C≡CCH3, COO (CH2)0-5CCCH3, CONR6 (CH2)0-5CCCH3, and SO2 (CH2)0-5C═CCH3, each of which is optionally substituted by one, two, three, or four R7;
• each R6 is H;
• and
• each R7 is independently H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, F, Br, Cl, CF3, NO2, OH, OCH3, CN, or amino group unsubstituted or substituted with methyl, ethyl, or propyl.